<DOC>
	<DOCNO>NCT00578071</DOCNO>
	<brief_summary>The primary purpose trial define maximum tolerate and/or recommended phase II dose combination panitumumab , oxaliplatin capecitabine patient undergo radiation therapy carcinoma thoracic esophagus gastroesophageal junction . An additional primary objective describe frequency nature grade III/IV grade I/II toxicity associate regimen . Secondary objective include describe 1-year disease-free survival overall survival rate well estimate clinical pathologic complete response rate associate regimen .</brief_summary>
	<brief_title>Phase I/II Study Panitumumab , Capecitabine Oxaliplatin w EBRT Esophageal Cancer</brief_title>
	<detailed_description>This study phase I/II design . For study administration panitumumab consider investigational . Pretreatment : Part regular cancer care disease stag include Chest/Abdomen CT Scan , upper endoscopic ultrasound , PET scan , J-Tube Placement ( clinically indicate ) , bronchoscopy ( per clinician judgment ) , ECG , baseline laboratory study . During Treatment Weeks 1-5.5 Radiation Therapy ( RT ) /Chemotherapy : - RT ( 180 cGy/fx , Mon-Fri ) day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 36-38 . - Panitumumab ( per dose level ) day 1 , 15 , 29 . - Oxaliplatin ( per dose level ) day 1 , 8 , 15 , 22 , 29 , 36 . - Capecitabine ( per dose level M-F ) 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-38 .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>18 year age old . Histologically cytologically document squamous cell carcinoma Siewert 's classification adenocarcinoma esophagus proximal stomach T14 , N02 , M01 , bimodality treatment chemotherapy radiation therapy indicate . Measurable Disease ECOG Performance Status 01 Laboratory value must follow : Absolute neutrophil count &gt; = 2,000/mm3 , Platelets &gt; = 100,000/mm3 , Hemoglobin &gt; 9.0 , Total bilirubin &lt; 1.5 x institutional upper normal limit , Serum creatinine &lt; 1.5 x institutional upper normal limit , AST ALT &lt; 3x institutional upper normal limit , Magnesium equal high institutional low limit , Creatinine clearance Estimated &gt; 40 ml/min , Calcium &gt; low limit normal . Not pregnant lactating . Negative pregnancy test within 72 hour prior registration ( female patient childbearing potential ) . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Life expectancy must &gt; 3 month . No serious poorly control medical psychological condition could exacerbate treatment would seriously complicate compliance protocol . Able swallow capecitabine ( whole crush tablet liquid disperse ) patient may G J tube . No condition would significantly compromise intestinal absorption study drug . Tumors extend level thoracic inlet beyond 5 cm gastroesophageal junction . Patients radiographic bronchoscopic evidence esophageal perforation . Patients know evidence brain metastasis , lymphangitic lung metastasis , carcinomatous meningitis . Dementia significantly alter mental status Major surgery within 4 week start study treatment Prior chemotherapy , radiation therapy , hormonal biologic therapy within past 6 month . Subjects require chronic use immunosuppressive agent ( e.g. , methotrexate , cyclosporine , corticosteroid ) Currently require medication may interact metabolism disposition capecitabine/5FU : dipyridamole , folinic acid , allopurinol , trimethoprim , misonidazole , metoclopramide , flucytosine cimetidine . Hypersensitivity platinum contain compound capecitabine excipients product . Prior unanticipated severe reaction fluoropyrimidine/platinum therapy , know sensitivity 5fluorouracil/platinum contain compound . Serious , uncontrolled , concurrent infection ( ) . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer . Peripheral neuropathy &gt; grade 1 Any follow within 24 week randomization : clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) . Uncontrolled gastrointestinal ulcer within 28 day randomization History interstitial pneumonitis pulmonary fibrosis , evidence interstitial pneumonitis pulmonary fibrosis baseline chest Xray CTscan Preexisting know bleed diathesis coagulopathy Plans continue use ketoconazole , phenytoin , phenobarbital , carbamazepine , rifampin , rifabutin St. John 's Wort , 14 day prior randomization . History hypersensitivity tetracycline Subject know human immunodeficiency virus positive Subjects know chronic active hepatitis B C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>esophageal cancer</keyword>
</DOC>